New Antiarrhythmic drugs in pediatric use: Amiodarone

T. Paul, P. Guccione

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Amiodarone, a class III antiarrhythmic agent, prolongs action potential duration and refractoriness of all cardiac structures. The drug is more rapidly metabolized in pediatric patients than in adults, but its kinetics are still unique compared with other drugs. Due to the unusual pharmacokinetic characteristics of amiodarone, treatment has to be started by administering loading doses, and there is a significant delay both in the achievement of the full antiarrhythmic effect and in the development of side effects. Amoidarone is a highly effective agent in pediatric patients with automatic and reentrant supraventricular tachycardia as well as in refractory atrial flutter. Efficacy in ventricular tachycardia has been shown to be variable depending on the underlying anatomical substrate. The incidence of side effects is lower than that observed in adult studies with similar duration of therapy but their incidence is still significant. Amiodarone treatment is associated with a significant risk of proarrhythmic effects, requiring hospitalization of the patient during the loading period.

Original languageEnglish
Pages (from-to)132-138
Number of pages7
JournalPediatric Cardiology
Volume15
Issue number3
DOIs
Publication statusPublished - May 1994

Fingerprint

Amiodarone
Anti-Arrhythmia Agents
Pediatrics
Atrial Flutter
Supraventricular Tachycardia
Incidence
Ventricular Tachycardia
Pharmaceutical Preparations
Action Potentials
Hospitalization
Therapeutics
Pharmacokinetics

Keywords

  • Amiodarone
  • Electrophysiology
  • Hemodynamics
  • Pharmacokinetics
  • Proarrhythmia
  • Systemic side effects

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Cardiology and Cardiovascular Medicine

Cite this

New Antiarrhythmic drugs in pediatric use : Amiodarone. / Paul, T.; Guccione, P.

In: Pediatric Cardiology, Vol. 15, No. 3, 05.1994, p. 132-138.

Research output: Contribution to journalArticle

@article{84e24f0891d94f278528444d6b51ef8e,
title = "New Antiarrhythmic drugs in pediatric use: Amiodarone",
abstract = "Amiodarone, a class III antiarrhythmic agent, prolongs action potential duration and refractoriness of all cardiac structures. The drug is more rapidly metabolized in pediatric patients than in adults, but its kinetics are still unique compared with other drugs. Due to the unusual pharmacokinetic characteristics of amiodarone, treatment has to be started by administering loading doses, and there is a significant delay both in the achievement of the full antiarrhythmic effect and in the development of side effects. Amoidarone is a highly effective agent in pediatric patients with automatic and reentrant supraventricular tachycardia as well as in refractory atrial flutter. Efficacy in ventricular tachycardia has been shown to be variable depending on the underlying anatomical substrate. The incidence of side effects is lower than that observed in adult studies with similar duration of therapy but their incidence is still significant. Amiodarone treatment is associated with a significant risk of proarrhythmic effects, requiring hospitalization of the patient during the loading period.",
keywords = "Amiodarone, Electrophysiology, Hemodynamics, Pharmacokinetics, Proarrhythmia, Systemic side effects",
author = "T. Paul and P. Guccione",
year = "1994",
month = "5",
doi = "10.1007/BF00796325",
language = "English",
volume = "15",
pages = "132--138",
journal = "Pediatric Cardiology",
issn = "0172-0643",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - New Antiarrhythmic drugs in pediatric use

T2 - Amiodarone

AU - Paul, T.

AU - Guccione, P.

PY - 1994/5

Y1 - 1994/5

N2 - Amiodarone, a class III antiarrhythmic agent, prolongs action potential duration and refractoriness of all cardiac structures. The drug is more rapidly metabolized in pediatric patients than in adults, but its kinetics are still unique compared with other drugs. Due to the unusual pharmacokinetic characteristics of amiodarone, treatment has to be started by administering loading doses, and there is a significant delay both in the achievement of the full antiarrhythmic effect and in the development of side effects. Amoidarone is a highly effective agent in pediatric patients with automatic and reentrant supraventricular tachycardia as well as in refractory atrial flutter. Efficacy in ventricular tachycardia has been shown to be variable depending on the underlying anatomical substrate. The incidence of side effects is lower than that observed in adult studies with similar duration of therapy but their incidence is still significant. Amiodarone treatment is associated with a significant risk of proarrhythmic effects, requiring hospitalization of the patient during the loading period.

AB - Amiodarone, a class III antiarrhythmic agent, prolongs action potential duration and refractoriness of all cardiac structures. The drug is more rapidly metabolized in pediatric patients than in adults, but its kinetics are still unique compared with other drugs. Due to the unusual pharmacokinetic characteristics of amiodarone, treatment has to be started by administering loading doses, and there is a significant delay both in the achievement of the full antiarrhythmic effect and in the development of side effects. Amoidarone is a highly effective agent in pediatric patients with automatic and reentrant supraventricular tachycardia as well as in refractory atrial flutter. Efficacy in ventricular tachycardia has been shown to be variable depending on the underlying anatomical substrate. The incidence of side effects is lower than that observed in adult studies with similar duration of therapy but their incidence is still significant. Amiodarone treatment is associated with a significant risk of proarrhythmic effects, requiring hospitalization of the patient during the loading period.

KW - Amiodarone

KW - Electrophysiology

KW - Hemodynamics

KW - Pharmacokinetics

KW - Proarrhythmia

KW - Systemic side effects

UR - http://www.scopus.com/inward/record.url?scp=0028276843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028276843&partnerID=8YFLogxK

U2 - 10.1007/BF00796325

DO - 10.1007/BF00796325

M3 - Article

C2 - 8047495

AN - SCOPUS:0028276843

VL - 15

SP - 132

EP - 138

JO - Pediatric Cardiology

JF - Pediatric Cardiology

SN - 0172-0643

IS - 3

ER -